Lifestyle

Findings

Lyme disease antibody eyed

Shutterstock

There is no escaping them: Ticks are everywhere in Massachusetts. The state had one of the highest infection rates of Lyme disease in the country last year, with 3,646 reported cases.

Lyme disease can be successfully treated with antibiotics — if it’s detected. One-quarter of people don’t develop the characteristic bull’s-eye rash following the bite of an infected tick, and untreated infection can lead to debilitating symptoms such as arthritis and nerve pain.

Advertisement

A vaccine to prevent Lyme disease was pulled from pharmacy shelves in 2002 by manufacturer GlaxoSmithKline amid poor sales and alleged safety concerns, and there has been no replacement. Now, researchers at the University of Massachusetts Medical School are trying to develop an alternative way to prevent infection: a drug that could be administered to those at risk annually, just before tick season.

Though it sounds like the flu shot, the drug is not a vaccine, which activates the immune system against an invader. Instead, it is a pre-exposure prophylaxis, a molecule ready to kill bacteria immediately, similar to pills taken to ward off malaria when traveling abroad. “You take the medicine before you’re going to be exposed,” says lead researcher Mark Klempner, executive vice chancellor at MassBiologics, the nonprofit drug research and manufacturing arm of UMass.

Get The Weekender in your inbox:
The Globe's top picks for what to see and do each weekend, in Boston and beyond.
Thank you for signing up! Sign up for more newsletters here

Klempner and colleagues presented positive results from mouse studies at two infectious disease conferences last month, but the details have yet to be reviewed by other scientists or published.

The drug is a monoclonal antibody, a small molecule that binds to only one substance. In this case, the antibody binds and kills the bacteria in the gut of infected ticks that cause Lyme disease.

An antibody has several potential advantages over the previously withdrawn vaccine against Lyme disease, which required three doses over six months to achieve full protection and was only approved for those 15 to 70 years old. Klempner expects an antibody to provide immediate protection and be safe for all ages, including children.

Advertisement

To find the drug, the researchers injected mice engineered to produce human antibodies with proteins from Borrelia burgdorferi, the bacteria that causes Lyme disease in North America. Out of 593 human antibodies isolated from the mice, they narrowed the group down to four that are highly potent against B. burgdorferi and two other Borrelia species that cause Lyme disease in Europe.

Those final four were then tested in mice bitten by six infected ticks. “All four of them, at a certain dose, provided 100 percent protection compared to an irrelevant antibody,” says Klempner.

Finally, the team identified the antibody with the longest circulation time, hoping it will provide at least six months of protection in humans, and are now testing that drug’s safety in animal tissues and organs. Klempner hopes to initiate human clinical trials as early as 2016.

MEGAN SCUDELLARI

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.